The American investment company Bain Capital LP is considering the possibility of selling the assets of Tanabe Pharma Corp., which are located outside Japan. This is reported by foreign media.
Bain Capital has engaged a consultant to prepare for the proposed sale of Tanabe shares in 2026. The value of the assets is estimated at $400-500 million.
In early 2025, Bain Capital entered into an agreement to acquire Mitsubishi Tanabe Pharma Corp. for 510 billion yen ($3.3 billion). On December 1, the company officially changed its name to Tanabe Pharma Corp.
Tanabe Pharma is a pharmaceutical division of the Japanese Mitsubishi Chemical Group. The company is represented in Japan, North America, Europe, the Middle East and some other Asian markets. Tanab develops drugs in the field of immunology, diabetes, diseases of the central nervous system and metabolic disorders.
Bain Capital LP is an American private equity firm headquartered in Boston, Massachusetts. The company specializes in private and venture capital investments, lending, public investments and real estate.
Read also in our Telegram channel "Mergers and acquisitions. AK&M».
